ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
dc.date.accessioned | 2017-02-27T22:28:40Z | |
dc.date.available | 2017-02-27T22:28:40Z | |
dc.date.issued | 2012-10-01 | |
dc.identifier.citation | Zhang, Z., J. Yan, Y. Chang, S. Shidu Yan, and H. Shi. "Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases." Current Medicinal Chemistry 18.28 (2011): 4335-343. | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23280 | |
dc.description.abstract | Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor responsible for cellular and tissue adaption to low oxygen tension. HIF-1, a heterodimer consisting of a constitutively expressed β subunit and an oxygen-regulated α subunit, regulates a series of genes that participate in angiogenesis, iron metabolism, glucose metabolism, and cell proliferation/survival. The activity of HIF-1 is controlled by post-translational modifications on different amino acid residues of its subunits, mainly the alpha subunit. Besides in ischemic stroke (see review [1]), emerging evidence has revealed that HIF-1 activity and expression of its down-stream genes, such as vascular endothelial growth factor and erythropoietin, are altered in a range of neurodegenerative diseases. At the same time, experimental and clinical evidence has demonstrated that regulating HIF-1 might ameliorate the cellular and tissue damage in the neurodegenerative diseases. These new findings suggest HIF-1 as a potential medicinal target for the neurodegenerative diseases. This review focuses on HIF-1α protein modifications and HIF-1’s potential neuroprotective roles in Alzheimer’s (AD), Parkinson’s (PD), Huntington’s diseases (HD), and amyotrophic lateral sclerosis (ALS). | en_US |
dc.publisher | Bentham Science Publishers | en_US |
dc.subject | AD | en_US |
dc.subject | ALS | en_US |
dc.subject | EPO | en_US |
dc.subject | HD | en_US |
dc.subject | HIF-1 | en_US |
dc.subject | VEGF | en_US |
dc.subject | Protein modification | en_US |
dc.subject | Prolyl hydroxylase inhibitor | en_US |
dc.subject | Iron chelator | en_US |
dc.subject | 2-oxoglutarate analogues | en_US |
dc.subject | Cobalt | en_US |
dc.subject | Neurodegenerative diseases | en_US |
dc.title | Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Yan, Shirley Shidu | |
kusw.kudepartment | Pharmacology & Toxicology | en_US |
dc.identifier.doi | 10.2174/092986711797200426 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
-
Pharmacy Scholarly Works [299]